Developer docs
API playgroundTry for free, no card

Search company profiles

Oncolab

Full company profile

uuid003rsgc

Namestring
Oncolab
Legal namestring
OncoLab Co., Ltd.
Websiteurl
oncolab.co.kr
Company typeenum
Private
Founded yearint
2024
Descriptiontext

OncoLab Co., Ltd. is a South Korean preclinical biotech founded in May 2024 by CEO Jongseong Kim and CTO Doogie Oh, both with 20+ years of nanogel research experience. The company is developing ANGel, a hydrogel microparticle-based precision formulation and delivery platform designed for peritumoral/perilesional subcutaneous administration in oncology. ANGel integrates localized exposure design, sustained release profile, and modular combination architecture, working with approved antibodies and small-molecule oncology assets to deliver bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level rather than through molecular redesign. The lead program, ANGel-TNBC01/02, targets Triple Negative Breast Cancer and is supported by preclinical data showing >3x improvement in median overall survival versus an approved hyaluronidase comparator; the pipeline additionally includes ANGel-PSC01/02 for prostate cancer and ANGel-Dox01,02 for next-generation antibody/small-molecule co-delivery.

The company operates a B2B partnering-first business model, targeting global pharma and biotech counterparties for platform out-licensing, co-development, and milestone/royalty agreements with multi-layer economics (upfront + development milestones + royalties). Its go-to-market is structured as a data-driven conversion process: technical meeting → PoC design → option/co-development/licensing deal. Headquartered at the Chungbuk Center for Creative Economy and Innovation in Cheongju-si with research operations at the OncoLab Research Institute in Goyang-si, OncoLab holds Korean patent applications filed in 2025, publications in high-impact journals (Nature, PNAS, Nature Communications, JACS, Advanced Healthcare Materials), and has been selected for Korea's Deep Tech TIPS program, the KIPA Chairman's Award (September 2025), and the BIO Europe Startup Spotlight (Top 8, November 2025). Pre-A funding of 1 billion KRW from FuturePlay was secured in November 2025 to advance the platform toward an IND filing targeted for 2026 and global clinical entry.

Short descriptiontext

OncoLab is a South Korean preclinical biotech developing ANGel, a hydrogel microparticle drug-delivery platform that reformulates approved oncology antibodies and small molecules into localized, sustained-release combination therapies. It serves global pharma/biotech partners via out-licensing and co-development deals, with lead indication Triple Negative Breast Cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCheongju, South Korea
HQ citystring
Cheongju
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology platform, drug delivery technology, cancer therapeutics, hydrogel microparticles, pharmaceutical licensing
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-Oncology Drug Delivery Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Out-Licensing
TypeLicensing Royalties
Description

B2B partnering-first model targeting global pharma/biotech companies for platform technology licensing. Multi-layer economics structure including upfront payments, development milestones, and royalties. Designed for programs where approved or clinically validated assets can be upgraded via ANGel formulation.

oncolab.co.kr
2Co-Development Agreements
TypeProfessional Services
Description

Staged co-development partnerships where preclinical and GLP datasets transition into option/co-development/licensing structures aligned to decision-ready evidence. Includes funded research components where applicable.

oncolab.co.kr
3Milestone Payments
TypeLicensing Royalties
Description

Structured deal pathways with option agreements converting to full co-development deals, with development and regulatory milestone payments tied to IND filing, clinical progression, and approval.

oncolab.co.kr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ANGel
Description

Hydrogel microparticle-based precision formulation and delivery platform for immuno-oncology treatment. Designed for peritumoral/subcutaneous administration, combining antibody surface binding and small molecule payload loading for localized sustained release therapy targeting solid tumors including Triple Negative Breast Cancer.

oncolab.co.kr
Core offering1 text field

OncoLab develops the ANGel platform, a hydrogel microparticle-based precision formulation and delivery technology designed for peritumoral/perilesional subcutaneous administration. The platform reformulates approved antibodies and small molecule oncology assets into localized, sustained-release combination therapies, expressing bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level without molecular redesign. Its lead clinical validation program targets Triple Negative Breast Cancer (ANGel-TNBC01/02), with additional pipeline programs in prostate cancer and next-generation co-delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • >3× improvement in preclinical mOS for TNBC vs approved comparator (~18 months)
+2 more records
Product overview1 text field

Oncolab (OncoLaB) is a biotech company developing ANGel, a modular hydrogel microparticle-based drug delivery platform for immuno-oncology. The platform combines antibody surface binding and small molecule payload loading in a single formulation to achieve bispecific-inspired multi-mechanism and ADC-like effects through reformulation of approved antibodies and oncology drugs. The product portfolio includes the core ANGel platform, with lead program ANGel-TNBC01/02 for Triple Negative Breast Cancer, ANGel-PSC01/02 for Prostate Cancer, and ANGel-Dox01,02 for next-generation co-delivery applications.

Product and service4 records
1ANGel Platform
CategoryCore Technology Platform
Description

Next-generation immuno-oncology drug delivery platform based on hydrogel microparticle precision formulation and delivery for peritumoral/perilesional subcutaneous administration with sustained release. Integrates multi-antibody function (bispecific-inspired multi-mechanism) and payload-driven drug effect (ADC-like action) in a single dosage form by reformulating approved antibodies and small molecule oncology assets without molecular redesign. Licensed or co-developed with global pharma/biotech partners.

2ANGel-TNBC01/02
CategoryLead Pipeline Program
Description

Lead ANGel clinical validation program for Triple Negative Breast Cancer (TNBC), designed to deliver GLP toxicology, humanized mouse efficacy proof-of-concept, and CMC standardization as a clinical entry proof package for partnering.

3ANGel-PSC01/02
CategoryPipeline Program
Description

ANGel pipeline program for prostate cancer indication exploration, with initial efficacy exploration and expansion feasibility assessment planned across multiple years.

4ANGel-Dox01,02
CategoryPipeline Program
Description

Next-generation ANGel pipeline program for co-delivery of multiple therapeutic modalities, including antibody and small molecule payload loading with established release conditions and in vitro validation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Halozyme's ENHANZE platform reformulates approved IV biologics for subcutaneous delivery via a single injected enzyme, generating royalty-bearing licensing deals with Roche, Pfizer, AbbVie, and others — closely analogous to Oncolab's B2B reformulation/licensing motion targeting approved oncology antibodies.

TypeDirect peer
Description

Cristal Therapeutics develops polymeric nanomedicines encapsulating chemotherapy and other payloads for targeted oncology delivery — directly comparable platform-stage nanomedicine company working on localized/targeted oncology therapeutics.

TypeBroad incumbent
Description

Daiichi Sankyo pioneered the ADC modality with Enhertu and Datroway; a primary strategic incumbent whose ADC platforms compete with ANGel's ADC-like payload action and whose antibodies are potential reformulation targets.

TypeDirect peer
Description

BIND developed Accurins — targeted polymeric nanoparticles for oncology payloads — and was acquired by Pfizer; its platform approach (nanoparticle + payload + targeting) is the closest historical analog to ANGel.

TypeDirect peer
Description

Nanobiotix develops nanoparticle-based therapeutics for solid tumors, including radioenhancers and immune-oncology combinations delivered locally — the closest direct analog to Oncolab's nanoparticle/hydrogel-based local immuno-oncology delivery approach.

TypeBroad incumbent
Description

Roche is the global leader in bispecific antibodies (Hemlibra, Vabysmo, Lunsumio, Columvi) and immuno-oncology combinations — the dominant incumbent whose approved antibodies are potential ANGel reformulation substrates.

TypeDirect peer
Description

Tarveda develops miniature drug conjugates (nanoparticle-payload conjugates) that combine targeted delivery with payload action in oncology — overlapping with ANGel's antibody+small-molecule payload-in-one-particle concept.

TypeBroad incumbent
Description

AstraZeneca operates in immuno-oncology (Imfinzi) and bispecifics (Datopotamab deruxtecan via partnership) and is one of the most likely pharma partners/licensors for ANGel — and a benchmark for the bispecific/ADC competition.

TypeEmerging player
Description

Bolt is a clinical-stage immuno-oncology company developing bispecific immune-stimulating antibody conjugates (ISACs) that combine antibody targeting with immune agonism — adjacent to ANGel's bispecific-inspired + payload-action concept at the molecular level.

TypeEmerging player
Description

Cytovation develops intratumorally administered oncology biologics (CyPepTide platform) — a clinical-stage precedent that validates peritumoral/local administration as a viable oncology delivery strategy analogous to ANGel's SC administration.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncolab

Immuno-Oncology Drug Delivery Platformoncolab.co.kr

OncoLab is a South Korean preclinical biotech developing ANGel, a hydrogel microparticle drug-delivery platform that reformulates approved oncology antibodies and small molecules into localized, sustained-release combination therapies. It serves global pharma/biotech partners via out-licensing and co-development deals, with lead indication Triple Negative Breast Cancer.

What Oncolab does

OncoLab Co., Ltd. is a South Korean preclinical biotech founded in May 2024 by CEO Jongseong Kim and CTO Doogie Oh, both with 20+ years of nanogel research experience. The company is developing ANGel, a hydrogel microparticle-based precision formulation and delivery platform designed for peritumoral/perilesional subcutaneous administration in oncology. ANGel integrates localized exposure design, sustained release profile, and modular combination architecture, working with approved antibodies and small-molecule oncology assets to deliver bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level rather than through molecular redesign. The lead program, ANGel-TNBC01/02, targets Triple Negative Breast Cancer and is supported by preclinical data showing >3x improvement in median overall survival versus an approved hyaluronidase comparator; the pipeline additionally includes ANGel-PSC01/02 for prostate cancer and ANGel-Dox01,02 for next-generation antibody/small-molecule co-delivery.

The company operates a B2B partnering-first business model, targeting global pharma and biotech counterparties for platform out-licensing, co-development, and milestone/royalty agreements with multi-layer economics (upfront + development milestones + royalties). Its go-to-market is structured as a data-driven conversion process: technical meeting → PoC design → option/co-development/licensing deal. Headquartered at the Chungbuk Center for Creative Economy and Innovation in Cheongju-si with research operations at the OncoLab Research Institute in Goyang-si, OncoLab holds Korean patent applications filed in 2025, publications in high-impact journals (Nature, PNAS, Nature Communications, JACS, Advanced Healthcare Materials), and has been selected for Korea's Deep Tech TIPS program, the KIPA Chairman's Award (September 2025), and the BIO Europe Startup Spotlight (Top 8, November 2025). Pre-A funding of 1 billion KRW from FuturePlay was secured in November 2025 to advance the platform toward an IND filing targeted for 2026 and global clinical entry.

Oncolab firmographics

Firmographics
Name
Oncolab
Legal name
OncoLab Co., Ltd.
Website
https://oncolab.co.kr
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
OncoLab is a South Korean preclinical biotech developing ANGel, a hydrogel microparticle drug-delivery platform that reformulates approved oncology antibodies and small molecules into localized, sustained-release combination therapies. It serves global pharma/biotech partners via out-licensing and co-development deals, with lead indication Triple Negative Breast Cancer.
Ownership category
akta.pro rank

Oncolab industry classification

Industry
Product category
Immuno-Oncology Drug Delivery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Immuno-oncology platform
  • Drug delivery technology
  • Cancer therapeutics
  • Hydrogel microparticles
  • Pharmaceutical licensing

Where Oncolab is headquartered

Location

Headquarters

HQ city
Cheongju
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Oncolab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Out-Licensing: B2B partnering-first model targeting global pharma/biotech companies for platform technology licensing. Multi-layer economics structure including upfront payments, development milestones, and royalties. Designed for programs where approved or clinically validated assets can be upgraded via ANGel formulation.
  2. Co-Development Agreements: Staged co-development partnerships where preclinical and GLP datasets transition into option/co-development/licensing structures aligned to decision-ready evidence. Includes funded research components where applicable.
  3. Milestone Payments: Structured deal pathways with option agreements converting to full co-development deals, with development and regulatory milestone payments tied to IND filing, clinical progression, and approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Oncolab product offering

Product offering

Core offering

OncoLab develops the ANGel platform, a hydrogel microparticle-based precision formulation and delivery technology designed for peritumoral/perilesional subcutaneous administration. The platform reformulates approved antibodies and small molecule oncology assets into localized, sustained-release combination therapies, expressing bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level without molecular redesign. Its lead clinical validation program targets Triple Negative Breast Cancer (ANGel-TNBC01/02), with additional pipeline programs in prostate cancer and next-generation co-delivery.

Product overview

Oncolab (OncoLaB) is a biotech company developing ANGel, a modular hydrogel microparticle-based drug delivery platform for immuno-oncology. The platform combines antibody surface binding and small molecule payload loading in a single formulation to achieve bispecific-inspired multi-mechanism and ADC-like effects through reformulation of approved antibodies and oncology drugs. The product portfolio includes the core ANGel platform, with lead program ANGel-TNBC01/02 for Triple Negative Breast Cancer, ANGel-PSC01/02 for Prostate Cancer, and ANGel-Dox01,02 for next-generation co-delivery applications.

Differentiator

Problem solved

Functional benefit

Brands

  • ANGel: Hydrogel microparticle-based precision formulation and delivery platform for immuno-oncology treatment. Designed for peritumoral/subcutaneous administration, combining antibody surface binding and small molecule payload loading for localized sustained release therapy targeting solid tumors including Triple Negative Breast Cancer.

Products and services

  • ANGel Platform Next-generation immuno-oncology drug delivery platform based on hydrogel microparticle precision formulation and delivery for peritumoral/perilesional subcutaneous administration with sustained release. Integrates multi-antibody function (bispecific-inspired multi-mechanism) and payload-driven drug effect (ADC-like action) in a single dosage form by reformulating approved antibodies and small molecule oncology assets without molecular redesign. Licensed or co-developed with global pharma/biotech partners.
  • ANGel-TNBC01/02 Lead ANGel clinical validation program for Triple Negative Breast Cancer (TNBC), designed to deliver GLP toxicology, humanized mouse efficacy proof-of-concept, and CMC standardization as a clinical entry proof package for partnering.
  • ANGel-PSC01/02 ANGel pipeline program for prostate cancer indication exploration, with initial efficacy exploration and expansion feasibility assessment planned across multiple years.
  • ANGel-Dox01,02 Next-generation ANGel pipeline program for co-delivery of multiple therapeutic modalities, including antibody and small molecule payload loading with established release conditions and in vitro validation.

Quantifiable outcome

  • >3× improvement in preclinical mOS for TNBC vs approved comparator (~18 months)
  • +2 more outcomes

Companies that use Oncolab

Customer profile

Segments2 records

Ideal customer profiles1 record

Oncolab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Oncolab partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves12 records

Expansion highlights6 records

Oncolab competitors and assessment

Company assessment

Direct peers

  • Halozyme Therapeutics: Halozyme's ENHANZE platform reformulates approved IV biologics for subcutaneous delivery via a single injected enzyme, generating royalty-bearing licensing deals with Roche, Pfizer, AbbVie, and others — closely analogous to Oncolab's B2B reformulation/licensing motion targeting approved oncology antibodies.
  • Cristal Therapeutics: Cristal Therapeutics develops polymeric nanomedicines encapsulating chemotherapy and other payloads for targeted oncology delivery — directly comparable platform-stage nanomedicine company working on localized/targeted oncology therapeutics.
  • BIND Therapeutics (acquired by Pfizer): BIND developed Accurins — targeted polymeric nanoparticles for oncology payloads — and was acquired by Pfizer; its platform approach (nanoparticle + payload + targeting) is the closest historical analog to ANGel.
  • Nanobiotix: Nanobiotix develops nanoparticle-based therapeutics for solid tumors, including radioenhancers and immune-oncology combinations delivered locally — the closest direct analog to Oncolab's nanoparticle/hydrogel-based local immuno-oncology delivery approach.
  • Tarveda Therapeutics: Tarveda develops miniature drug conjugates (nanoparticle-payload conjugates) that combine targeted delivery with payload action in oncology — overlapping with ANGel's antibody+small-molecule payload-in-one-particle concept.

Broad incumbents

  • Daiichi Sankyo: Daiichi Sankyo pioneered the ADC modality with Enhertu and Datroway; a primary strategic incumbent whose ADC platforms compete with ANGel's ADC-like payload action and whose antibodies are potential reformulation targets.
  • Roche: Roche is the global leader in bispecific antibodies (Hemlibra, Vabysmo, Lunsumio, Columvi) and immuno-oncology combinations — the dominant incumbent whose approved antibodies are potential ANGel reformulation substrates.
  • AstraZeneca: AstraZeneca operates in immuno-oncology (Imfinzi) and bispecifics (Datopotamab deruxtecan via partnership) and is one of the most likely pharma partners/licensors for ANGel — and a benchmark for the bispecific/ADC competition.

Emerging players

  • Bolt Biotherapeutics: Bolt is a clinical-stage immuno-oncology company developing bispecific immune-stimulating antibody conjugates (ISACs) that combine antibody targeting with immune agonism — adjacent to ANGel's bispecific-inspired + payload-action concept at the molecular level.
  • Cytovation: Cytovation develops intratumorally administered oncology biologics (CyPepTide platform) — a clinical-stage precedent that validates peritumoral/local administration as a viable oncology delivery strategy analogous to ANGel's SC administration.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Oncolab social profiles

Digital presence

Oncolab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncolab leadership team

Management profile

Number of profiles

Profiles9 records

Oncolab funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncolab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncolab

What does Oncolab do?

OncoLab develops the ANGel platform, a hydrogel microparticle-based precision formulation and delivery technology designed for peritumoral/perilesional subcutaneous administration. The platform reformulates approved antibodies and small molecule oncology assets into localized, sustained-release combination therapies, expressing bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level without molecular redesign. Its lead clinical validation program targets Triple Negative Breast Cancer (ANGel-TNBC01/02), with additional pipeline programs in prostate cancer and next-generation co-delivery.

Is Oncolab a public or private company?

Oncolab is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oncolab founded?

Oncolab was founded in 2024. It employs 1 to 10 people.

Where is Oncolab based?

Oncolab is headquartered in Cheongju, South Korea, in the Asia region.

How does Oncolab make money?

Three revenue lines are on record. Platform Out-Licensing is the primary driver. The others are co-Development Agreements and milestone Payments.

Who are Oncolab's main competitors?

Direct peers on record are Halozyme Therapeutics, Cristal Therapeutics, BIND Therapeutics (acquired by Pfizer), Nanobiotix and Tarveda Therapeutics. Broad incumbents are Daiichi Sankyo, Roche and AstraZeneca. Emerging players are Bolt Biotherapeutics and Cytovation.

Does Oncolab have an API?

No public API is recorded for Oncolab.

What industry is Oncolab in?

Oncolab's product category is Immuno-Oncology Drug Delivery Platform. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartuptodayBio startup Oncolab secures 1 billion won in pre-A investment from Future PlayBio startup Oncolab has secured 1 billion won in pre-A investment from Future Play to advance its immune cancer platform 'ANGel', which uses biocompatible microgels to deliver antibodies and anticancer drugs directly to tumors while minimizing systemic toxicity. The ANGel platform is being developed initially for triple-negative breast cancer with a modular strategy allowing expansion to other solid tumors such as prostate cancer and non-small cell lung cancer. Oncolab is currently conducting GLP toxicity tests and humanized mouse efficacy tests, targeting an IND submission in 2026 for global clinical trials.PlatumBio startup 'Oncolab' secures 1 billion won pre-A investment from Future PlayOncolab, a bio startup, has secured 1 billion won in pre-A funding from Future Play to advance its immune cancer platform 'ANGel'. The company aims to initiate global clinical trials and expand its GMP capacity, targeting cancers such as triple-negative breast cancer and other solid tumors.AsiaeBio startup Oncolab secures pre-A investment from FuturePlayBio startup Oncolab announced on the 11th that it secured 1 billion won in Pre-A investment from Future Play for its immuno-oncology platform 'ANGel'. The ANGel platform is a microgel-based precision drug delivery technology that combines multiple antibodies and anticancer drugs into single microparticles to simultaneously perform cancer cell recognition, immune activation, and anticancer drug release, aiming to minimize systemic toxicity while maximizing therapeutic efficacy. Oncolab is currently developing the technology with triple-negative breast cancer as its first indication and pursuing a modular platform strategy to expand to other solid tumors.